Critical Outcome Technologies (OTCQB:COTQF; TSX-V:COT) has appointed Bharatt Chowrira to its board.
Dr. Chowrira has more than 20 years of industry experience that spans progressively senior management positions, serving on and working with the boards of private and public companies. He is currently the president of Synlogic, a U.S. biopharmaceutical company focused on synthetic biotics.
In a statement, COTI chairman, John Drake, said Dr. Chowrira has been instrumental in several licensing and collaboration partnerships, and in raising significant amounts of equity for private and public companies. He is well versed in pipeline development, portfolio evaluation and prioritization, and intellectual property law matters.
Citing COTI’s innovative approach to addressing difficult to treat gynecological cancers, Dr. Chowrira said that selective targeting of the mutant forms of p53 protein, a central switch in a number of cancers, has been the focus of intense research in the field for a number of years, with limited success.
“COTI scientists may potentially have solved this puzzle and are currently evaluating their lead oral small molecule candidate in women with gynecological cancers,” he added. “If this compound is able to achieve efficacy in these patients, in my opinion this would be a major advance in this field.”